Skip to main content

Table 1 Characteristics of the patients (n = 40)

From: Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients

Age at vaccination (years); median (min, p25, p75, max) 60 (26, 54, 69, 76)
Sex (# males/# females) 19/21
Delay between vaccination and transplantation (months); median (min, p25, p75, max) 31 (6, 14, 42, 57)
Donor type (# MSD/MUD/ MMUD/Haplo) 8/26/1/5
Donor age at transplantation (years); median (min, p25, p75, max) 34 (18, 23, 46, 62)
Conditioning regimen (# patients)  
 Fludarabine + 2 Gy TBI 5
 Fludarabine + Melphalan 18
 Fludarabine + busulfan 4
 Cyclophosphamide + 12 Gy TBI 6
 Thiotepa + busulfan + fludarabine 2
 Sequential 3
 Fludarabine + Cyclophosphamide + 2 or 4 Gy TBI 2
ATG (# yes/no) 29/11
PTCY (# yes/no) 6 /34
Chronic GVHD  
 Never/only mild 29
 Prior moderate/severe solved* 2
 Ongoing moderate/severe 9
Rituximab (none or ≥ 2yrs, ≥ 1 but < 2 yrs, > 6 months but < 1 yr), # of patients 28, 5, 7
Systemic immunosuppression at inclusion  
 None 26
 Tacrolimus 5
 Photopheresis 1
 Photopheresis + mPDN < 32 mg/day 1
 MMF 1
 MMF + mPDN < 32 mg/day 1
 Sirolimus 1
 Sirolimus + mPDN < 32 mg/day 2
 Photopheresis + ruxolitinib 2
  1. * and > 3 months out of systemic immunosuppression. MSD, HLA-identical sibling donor; MUD, 10/10 HLA-matched unrelated donor; MMUD, 1/10 HLA-mismatched unrelated donor; Haplo, HLA-haploidentical donor; TBI, total body irradiation; ATG, anti-thymocyte globulin; PTCY, post-transplant cyclophosphamide; MMF, mycophenolate mofetil; mPDN, methyl-prednisolone